Table 2 The M-MDSCs frequency in healthy people and T2DM patients.

From: Increased monocytic myeloid-derived suppressor cells in type 2 diabetes correlate with hyperglycemic and was a risk factor of infection and tumor occurrence

Subjects

M-MDSCs frequency† (%)

Healthy population (n = 102)

0.93% (0.54, 1.20)

All T2DM patients (n = 77)

2.32% (1.29, 4.21)*

GGC (n = 17)

1.65% (0.79, 3.76)

PGC (n = 60)

2.54% (1.39, 4.32)*

  1. †The Data are expressed as median (interquartile range). GGC T2DM patients with good glycemic control (FPG ≤ 7.2 mmol/L and HbA1c ≤ 7.0%); PGC patients with poor glycemic control (FPG > 7.2 mmol/L or HbA1c > 7.0%). *Compared with the healthy population (P < 0.001). The frequency of M-MDSCs in all T2DM patients and the PGC group significantly higher than that in the healthy population (2.32% and 2.54% vs. 0.93%), but no significant difference between the GGC group and the healthy population (1.65% vs. 0.93%). The significance of the differences was assessed using non-parametric testing (Mann–Whitney U test).
Back to article page